Gregory W Severin1, Jesper T Jørgensen2, Stefan Wiehr3, Anna-Maria Rolle3, Anders E Hansen4, Andreas Maurer3, Mike Hasenberg5, Bernd Pichler3, Andreas Kjær2, Andreas I Jensen6. 1. The Hevesy Laboratory, DTU Nutech, Technical University of Denmark; Center for Nanomedicine and Theranostics, Technical University of Denmark. 2. Dept. of Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet and Cluster for Molecular Imaging, Faculty of Health Science, University of Copenhagen, Denmark. 3. Werner Siemens Imaging Center, Department for Preclinical Imaging and Radiopharmacy, Eberhard Karls University Tübingen, Tübingen, Germany. 4. Dept. of Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet and Cluster for Molecular Imaging, Faculty of Health Science, University of Copenhagen, Denmark; Center for Nanomedicine and Theranostics, Technical University of Denmark; Department of Micro- and Nanotechnology, DTU Nanotech, Technical University of Denmark. 5. University Duisburg-Essen, University Hospital, Institute for Experimental Immunology and Imaging, Essen, Germany. 6. The Hevesy Laboratory, DTU Nutech, Technical University of Denmark; Center for Nanomedicine and Theranostics, Technical University of Denmark. Electronic address: atije@dtu.dk.
Abstract
UNLABELLED: Preclinical studies involving (89)Zr often report significant bone accumulation, which is associated with dissociation of the radiometal from the tracer. However, experiments determining the uptake of unbound (89)Zr in disease models are not performed as routine controls. The purpose of the present study was to investigate the impact of free or weakly bound (89)Zr on PET quantifications in disease models, in order to determine if such control experiments are warranted. METHODS: Chemical studies were carried out to find a (89)Zr compound that would solubilize the (89)Zr as a weak chelate, thus mimicking free or weakly bound (89)Zr released in circulation. (89)Zr oxalate had the desired characteristics, and was injected into mice bearing FaDu and HT29 solid tumor xenografts, and mice infected in the lungs with the mold Aspergillus fumigatus, as well as in healthy controls (naïve). PET/CT or PET/MR imaging followed to quantify the distribution of the radionuclide in the disease models. RESULTS: (89)Zr oxalate was found to have a plasma half-life of 5.1 ± 2.3 h, accumulating mainly in the bones of all animals. Both tumor types accumulated (89)Zr on the order of 2-4 %ID/cm(3), which is comparable to EPR-mediated accumulation of certain species. In the aspergillosis model, the concentration of (89)Zr in lung tissue of the naïve animals was 6.0 ± 1.1 %ID/g. This was significantly different from that of the animals with advanced disease, showing 11.6 ± 1.8 %ID/g. CONCLUSIONS: Given the high levels of (89)Zr accumulation in the disease sites in the present study, we recommend control experiments mapping the biodistribution of free (89)Zr in any preclinical study employing (89)Zr where bone uptake is observed. Aqueous (89)Zr oxalate appears to be a suitable compound for such studies. This is especially relevant in studies where the tracer accumulation is based upon passive targeting, such as EPR.
UNLABELLED: Preclinical studies involving (89)Zr often report significant bone accumulation, which is associated with dissociation of the radiometal from the tracer. However, experiments determining the uptake of unbound (89)Zr in disease models are not performed as routine controls. The purpose of the present study was to investigate the impact of free or weakly bound (89)Zr on PET quantifications in disease models, in order to determine if such control experiments are warranted. METHODS: Chemical studies were carried out to find a (89)Zr compound that would solubilize the (89)Zr as a weak chelate, thus mimicking free or weakly bound (89)Zr released in circulation. (89)Zr oxalate had the desired characteristics, and was injected into mice bearing FaDu and HT29 solid tumor xenografts, and mice infected in the lungs with the mold Aspergillus fumigatus, as well as in healthy controls (naïve). PET/CT or PET/MR imaging followed to quantify the distribution of the radionuclide in the disease models. RESULTS: (89)Zr oxalate was found to have a plasma half-life of 5.1 ± 2.3 h, accumulating mainly in the bones of all animals. Both tumor types accumulated (89)Zr on the order of 2-4 %ID/cm(3), which is comparable to EPR-mediated accumulation of certain species. In the aspergillosis model, the concentration of (89)Zr in lung tissue of the naïve animals was 6.0 ± 1.1 %ID/g. This was significantly different from that of the animals with advanced disease, showing 11.6 ± 1.8 %ID/g. CONCLUSIONS: Given the high levels of (89)Zr accumulation in the disease sites in the present study, we recommend control experiments mapping the biodistribution of free (89)Zr in any preclinical study employing (89)Zr where bone uptake is observed. Aqueous (89)Zr oxalate appears to be a suitable compound for such studies. This is especially relevant in studies where the tracer accumulation is based upon passive targeting, such as EPR.
Authors: Stephen A Graves; Reinier Hernandez; Jesper Fonslet; Christopher G England; Hector F Valdovinos; Paul A Ellison; Todd E Barnhart; Dennis R Elema; Charles P Theuer; Weibo Cai; Robert J Nickles; Gregory W Severin Journal: Bioconjug Chem Date: 2015-09-10 Impact factor: 4.774
Authors: Mirkka Sarparanta; Jacob Pourat; Kathryn E Carnazza; Jun Tang; Navid Paknejad; Thomas Reiner; Mauri A Kostiainen; Jason S Lewis Journal: Nucl Med Biol Date: 2019-11-09 Impact factor: 2.408
Authors: Anne M Talkington; Morgan D McSweeney; Timothy Wessler; Marielle K Rath; Zibo Li; Tao Zhang; Hong Yuan; Jonathan E Frank; M Gregory Forest; Yanguang Cao; Samuel K Lai Journal: J Control Release Date: 2022-01-21 Impact factor: 11.467
Authors: Scott Edmonds; Alessia Volpe; Hilary Shmeeda; Ana C Parente-Pereira; Riya Radia; Julia Baguña-Torres; Istvan Szanda; Gregory W Severin; Lefteris Livieratos; Philip J Blower; John Maher; Gilbert O Fruhwirth; Alberto Gabizon; Rafael T M de Rosales Journal: ACS Nano Date: 2016-10-26 Impact factor: 15.881